HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Some Topical Analgesics Draw Outside US FDA’s Lines For Formulations And Indications

Executive Summary

FDA warns six businesses found selling directly to consumers topical formulations containing lidocaine outside the 0.5% to 4% concentration range allowed under OTC monographs for topical analgesics

You may also be interested in...



FDA warns on topical anesthetics

The agency advises consumers that lidocaine, tetracaine and other anesthetic drugs contained in skin-numbing products can reach the bloodstream and may cause life-threatening side effects. FDA's Jan. 16 public health advisory recommends that consumers looking at OTC or prescription topical anesthetics choose a product "that contains the lowest amount possible of medication that will relieve the pain" and apply it sparingly

Hemp Regulation Flags Raised By States Wave Tougher Compliance Cloud Over Industry

Without FDA regulatory pathway for hemp’s lawful use in supplements and food, some states are imposing more-stringent regulations while others allow sales of intoxicating ingredients not considered controlled substances as hemp derivatives.

Proliferation Of Intoxicating Hemp Ingredients Prompts Request For Federal Regulatory Pathway

US Cannabis Council says farm bill reauthorization is “key opportunity to tackle the national crisis caused by unregulated intoxicating hemp products” by limiting the variety of hemp derivatives which qualify as de-scheduled.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154543

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel